Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

2019989 citationsJournal Articlehybrid Open Access

Authors

Pembrolizumab is effective with a manageable safety profile in patients with MSI-H/dMMR CRC.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 38, Issue 1, pp. 11-19

Field-Weighted Citation Impact: 50.12